Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10, Bloomberg Earnings reports. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million.

Shares of Heron Therapeutics (NASDAQ HRTX) traded up 1.96% during midday trading on Thursday, reaching $15.60. 1,000,256 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $15.36 and its 200 day moving average price is $14.55. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $22.01.

HRTX has been the topic of a number of recent research reports. Cowen and Company reiterated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research note on Friday, May 26th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Friday, May 12th. Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 price objective (up from $30.00) on shares of Heron Therapeutics in a research note on Thursday, May 11th. Aegis reiterated a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $26.00 target price on shares of Heron Therapeutics in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $31.00.

TRADEMARK VIOLATION NOTICE: “Heron Therapeutics, Inc. (NASDAQ:HRTX) Releases Earnings Results, Beats Estimates By $0.10 EPS” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/heron-therapeutics-inc-nasdaqhrtx-releases-earnings-results-beats-estimates-by-0-10-eps.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.